Glykos is a late preclinical stage biopharmaceutical company working on best-in-class and first-in-class antibody-drug-conjugates (ADCs) with outstanding therapeutic index. Glykos has auristatin and DXd/exatecan linker-payloads for ADC generation, as well as hydrophilic linkers for application with novel payloads. The auristatin linker-payload mavg-MMAU improved the industry standard vedotin technology both in vivo efficacy and tolerability. Glykos’ pipeline has three preclinical ADC candidates. GLK-10 is directed to HER2-expressing solid tumors, GLK-21 targets the melanoma antigen TYRP-1, and GLK-33 is an anti-CD33 auristatin ADC against acute myeloid leukemia (AML). We welcome co-development opportunities with these therapeutic candidates as well as novel ADCs against collaborators' therapeutic targets. Glykos has recently entered into collaboration with Orion Pharma to develop novel ADCs against three oncology targets (https://glykos.fi/doc/Press%20release%20Glykos.pdf).